BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26177233)

  • 1. Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.
    Fazel J; Rötzer S; Seidl C; Feuerecker B; Autenrieth M; Weirich G; Bruchertseifer F; Morgenstern A; Senekowitsch-Schmidtke R
    Cancer Biol Ther; 2015; 16(10):1526-34. PubMed ID: 26177233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
    Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
    Autenrieth ME; Horn T; Kurtz F; Nguyen K; Morgenstern A; Bruchertseifer F; Schwaiger M; Blechert M; Seidl C; Senekowitsch-Schmidtke R; Gschwend JE; Scheidhauer K
    Urologe A; 2017 Jan; 56(1):40-43. PubMed ID: 27885456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
    Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
    J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
    Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
    Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
    Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
    Russell PJ; Davis K; Kingsley E; Humphreys J; Hanley J; O'Grady H; Pearce N
    Cell Biophys; 1994; 24-25():155-61. PubMed ID: 7736520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study.
    Autenrieth ME; Seidl C; Bruchertseifer F; Horn T; Kurtz F; Feuerecker B; D'Alessandria C; Pfob C; Nekolla S; Apostolidis C; Mirzadeh S; Gschwend JE; Schwaiger M; Scheidhauer K; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1364-1371. PubMed ID: 29644393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
    Beck R; Seidl C; Pfost B; Morgenstern A; Bruchertseifer F; Baum H; Schwaiger M; Senekowitsch-Schmidtke R
    Cancer Sci; 2007 Aug; 98(8):1215-22. PubMed ID: 17561973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
    Russell PJ; Plomley J; Shon IH; O'Grady H; Pearce N
    Cell Biophys; 1993; 22(1-3):27-47. PubMed ID: 7889541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
    Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
    Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of
    Feuerecker B; Michalik M; Hundshammer C; Schwaiger M; Bruchertseifer F; Morgenstern A; Seidl C
    Sci Rep; 2019 Jun; 9(1):8294. PubMed ID: 31165773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
    Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
    Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas.
    Bamias A; Bowles MJ; Krausz T; Williams G; Epenetos AA
    Int J Cancer; 1993 Jul; 54(6):899-903. PubMed ID: 8335396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.
    Boudousq V; Ricaud S; Garambois V; Bascoul-Mollevi C; Boutaleb S; Busson M; Quenet F; Colombo PE; Bardiès M; Kotzki PO; Navarro-Teulon I; Pèlegrin A; Pouget JP
    J Nucl Med; 2010 Nov; 51(11):1748-55. PubMed ID: 20956481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy.
    Russell PJ; Ho Shon I; Boniface GR; Izard ME; Philips J; Raghavan D; Walker KZ
    Urol Res; 1991; 19(4):207-13. PubMed ID: 1926654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
    Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
    Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.